CatalystWireBeta

Leadership Transition

In brief · summary, not quotable

Chief Executive Officer Bharatt Chowrira stepped down; Robert Lyne appointed Interim CEO.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your PRTC notes

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces that Bharatt Chowrira, PhD, JD, has stepped down today from his role as Chief Executive Officer (CEO) and as a member of the Board of Directors.

The Board of Directors has appointed Robert Lyne as Interim CEO with effect from today. Mr. Lyne joined PureTech as Chief Portfolio Officer in January 2024 and is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. He will continue to work closely with PureTech's Board and management team as the Company delivers on its strategic objectives.

Sharon Barber-Lui, Interim Chair of PureTech's Board of Directors, said: "The Board is grateful to Bharatt for his leadership and dedication to the Company over the past eight years. On behalf of the Board, I would like to sincerely thank him for his many contributions and wish him every success in the future. We remain focused on driving shareholder value, and Rob's extensive operational and capital markets experience will be key as he collaborates with the Board and engages with shareholders."

Robert Lyne, Interim Chief Executive Officer of PureTech, said: "I am honored to step into the role of Interim CEO and to continue working with this exceptional team at such an exciting time for the Company. PureTech has a high-value portfolio, and I look forward to building on the momentum we've generated as we advance our programs and deliver on meaningful milestones to create value for patients and shareholders."

  • Bharatt Chowrira, said: "It has been a true privilege to be part of PureTech's journey over the past eight years, including as CEO. I'm incredibly proud of what we've accomplished together-from advancing innovative science to progressing breakthrough clinical programs-and I leave with full confidence in the strength of the team and the exciting opportunities ahead for PureTech."

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note